nach oben

Erschienen in:

17.05.2023 | Review Article

Comparison of haploidentical–allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study

verfasst von: Li-qiang Wu, Li-fang Huang, Hui Yang, Bao-dong Ye, Jian-ping Sheng, Qing-hong Yu, Yan Yang, Jin-song Jia, Dong-hua Zhang, Sheng-yun Lin, Guang-sheng He, Jian-yong Li

Erschienen in: Annals of Hematology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

A retrospective analysis was conducted based on the clinical data from 60 patients older than 16 years from January 2016 to January 2021. All the patients were newly diagnosed with severe aplastic anemia (SAA) with an absolute neutrophil count (ANC) of zero. We compared the hematological response and survival of haploidentical–allogeneic hematopoietic stem cell transplantation (HID-HSCT) (n = 25) and intensive immunosuppressive therapy (IST) (n = 35) treatments. At six months, the overall response rate and complete response were significantly higher in the HID-HSCT group than those in the IST group (84.0% vs. 40.0%, P = 0.001; 80.0% vs. 17.1%, P = 0.001). With a median follow-up of 18.5 months (4.3~30.8 months), patients in the HID-HSCT group had longer overall survival and event-free survival (80.0% vs. 47.9%, P = 0.0419; 79.2% vs. 33.5%, P = 0.0048). These data suggested that HID-HSCT might be an effective alternative treatment option for adult patients with SAA with an ANC of zero, which requires further validation in an additional prospective study.

Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al (2016) Guidelines for the diagnosis and management of adult aplastic anemia. Br J Haematol 172(2):187–207. e-pub ahead of print 2015/11/17. https://doi.org/10.1111/bjh.13853CrossRefPubMed

Young NS (2018) Aplastic anemia. N Engl J Med 379(17):1643–1656. e-pub ahead of print 2018/10/26. https://doi.org/10.1056/NEJMra1413485CrossRefPubMedPubMedCentral

Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129(11):1428–1436. e-pub ahead of print 2017/01/18. https://doi.org/10.1182/blood-2016-08-693481CrossRefPubMed

Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H et al (2000) Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 96(6):2049–2054 e-pub ahead of print 2000/09/09CrossRefPubMed

Rosenfeld S, Follmann D, Nunez O, Young NS (2003) Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289(9):1130–1135. e-pub ahead of print 2003/03/08. https://doi.org/10.1001/jama.289.9.1130CrossRefPubMed

Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D et al (2015) Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med 373(1):35–47. e-pub ahead of print 2015/07/02. https://doi.org/10.1056/NEJMoa1414799CrossRefPubMedPubMedCentral

Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S et al (2014) Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 124(17):2698–2704. e-pub ahead of print 2014/08/21. https://doi.org/10.1182/blood-2014-05-574889CrossRefPubMedPubMedCentral

Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I et al (2019) Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv 3(20):3123–3131. e-pub ahead of print 2019/10/28. https://doi.org/10.1182/bloodadvances.2019000722CrossRefPubMedPubMedCentral

Yang D, Yang J, Hu X, Chen J, Gao L, Cheng H et al (2019) Aplastic anemia preconditioned with fludarabine, cyclophosphamide, and anti-thymocyte globulin. Ann Transplant 24:461–471. e-pub ahead of print 2019/08/10. https://doi.org/10.12659/AOT.915696CrossRefPubMedPubMedCentral

10.

Kekre N, Zhang Y, Zhang MJ, Carreras J, Ahmed P, Anderlini P et al (2017) Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica 102(7):1291–1298. e-pub ahead of print 2017/03/28. https://doi.org/10.3324/haematol.2017.164459CrossRefPubMedPubMedCentral

11.

Zhang Y, Wu L, Mo W, Zhou M, Li Y, Chen X et al (2019) Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: a retrospective single-center study. Biol Blood Marrow Transplant 25(8):1567–1575CrossRefPubMed

12.

Liu L, Zhang Y, Jiao W, Zhou H, Wang Q, Jin S et al (2020) Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia. Leukemia 34(12):3359–3369CrossRefPubMed

13.

Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V et al (2015) Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant 50(5):685–689CrossRefPubMed

14.

Xu LP, Wang SQ, Wu DP, Wang JM, Gao SJ, Jiang M et al (2016) Haplo-identical transplantation for acquired severe aplastic anemia in a multicentre prospective study. Br J Haematol 175(2):265–274. e-pub ahead of print 2016/06/29. https://doi.org/10.1111/bjh.14225CrossRefPubMed

15.

Xu LP, Jin S, Wang SQ, Xia LH, Bai H, Gao SJ et al (2017) Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol 10(1):25. e-pub ahead of print 2017/01/22. https://doi.org/10.1186/s13045-017-0398-yCrossRefPubMedPubMedCentral

16.

Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT et al (1988) Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br J Haematol 70(2):177–182. e-pub ahead of print 1988/10/01. https://doi.org/10.1111/j.1365-2141.1988.tb02460.xCrossRefPubMed

17.

Xu LP, Wang SQ, Ma YR, Gao SJ, Cheng YF, Zhang YY et al (2019) Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. J Hematol Oncol 12(1):87. e-pub ahead of print 2019/09/02. https://doi.org/10.1186/s13045-019-0775-9CrossRefPubMedPubMedCentral

18.

Yagasaki H, Shichino H, Ohara A, Kobayashi R, Yabe H, Ohga S et al (2014) Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as a treatment for fulminant aplastic anemia in children. Ann Hematol 93(5):747–752. e-pub ahead of print 2013/12/18. https://doi.org/10.1007/s00277-013-1984-xCrossRefPubMed

19.

Liu J, Lu XY, Cheng L, Yang Y, Lin SY, Yin H et al (2019) Clinical outcomes of immunosuppressive therapy for severe aplastic anemia patients with an absolute neutrophil count of zero. Hematology 24(1):492–497. e-pub ahead of print 2019/06/22. https://doi.org/10.1080/16078454.2019.1631424CrossRefPubMed

20.

Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M et al (2018) Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Am J Hematol 93(5):635–642. e-pub ahead of print 2018/01/30. https://doi.org/10.1002/ajh.25050CrossRefPubMed

21.

ElGohary G, El Fakih R, de Latour R, Risitano A, Marsh J, Schrezenmeier H et al (2020) Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transplant 55(10):1906–1917. e-pub ahead of print 2020/04/30. https://doi.org/10.1038/s41409-020-0897-2CrossRefPubMed

22.

Xu ZL, Huang XJ (2021) Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges. Bone Marrow Transplant 56(4):779–785. e-pub ahead of print 2020/12/17. https://doi.org/10.1038/s41409-020-01169-7CrossRefPubMed

23.

Iftikhar R, Chaudhry QUN, Anwer F, Neupane K, Rafae A, Mahmood SK et al (2021) Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Rev 47:100772. e-pub ahead of print 2020/11/15. https://doi.org/10.1016/j.blre.2020.100772CrossRefPubMed

24.

Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ et al (2005) Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 130(5):747–751. e-pub ahead of print 2005/08/24. https://doi.org/10.1111/j.1365-2141.2005.05667.xCrossRefPubMed

25.

Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X et al (2015) Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125(25):3956–3962. e-pub ahead of print 2015/05/06. https://doi.org/10.1182/blood-2015-02-627786CrossRefPubMed

26.

Im HJ, Koh KN, Seo JJ (2015) Haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Korean J Pediatr 58(6):199–205. e-pub ahead of print 2015/07/28. https://doi.org/10.3345/kjp.2015.58.6.199CrossRefPubMedPubMedCentral

27.

Viollier R, Passweg J, Gregor M, Favre G, Kuhne T, Nissen C et al (2005) Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol 84(1):47–55. e-pub ahead of print 2004/09/02. https://doi.org/10.1007/s00277-004-0930-3CrossRefPubMed

Titel: Comparison of haploidentical–allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study
verfasst von: Li-qiang Wu
Li-fang Huang
Hui Yang
Bao-dong Ye
Jian-ping Sheng
Qing-hong Yu
Yan Yang
Jin-song Jia
Dong-hua Zhang
Sheng-yun Lin
Guang-sheng He
Jian-yong Li
Publikationsdatum: 17.05.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 8/2023
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05256-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Operation bei Blasenkrebs/© anistidesign / Fotolia, Medizinische Fachangestellte sitzt erschöpft auf der Treppe/© Courtney Haas / peopleimages.com /stock.adobe.com (Symbolbild mit Fotomodell), Mann wird von Ärztin untersucht/© Tashi-Delek, Getty Images, iStock (Symbolbild mit Fotomodellen)

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia

Sufficient vitamin D is favorable for children with persistent and chronic immune thrombocytopenia

Therapy results in pediatric Hodgkin lymphoma — does less mean better? Experience from a single children’s oncology center

Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution

N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study

Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States